The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The rise of fragment-based drug discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Self-citationA decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Page, M. I., & Jencks, W. P. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1678 · Cited by 1,014
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Cited by
Chemistry and Biology Of Multicomponent Reactions
Dömling, A., Wang, W., & Wang, K. (2012) · Chemical Reviews · doi:10.1021/cr100233r · Cited by 2,547
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013) · Chemical Reviews · doi:10.1021/cr200409f · Cited by 1,896
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Protein structure-based drug design: from docking to molecular dynamics
Śledź, P., & Caflisch, A. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.10.010 · Cited by 565
Modulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
The Future of Bioorthogonal Chemistry
Devaraj, N. K. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00251 · Cited by 491
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
Visible-light induced dearomatization reactions
Cheng, Y.-Z., Feng, Z., Zhang, X., & You, S.-L. (2022) · Chemical Society Reviews · doi:10.1039/c9cs00311h · Cited by 366
Modular click chemistry libraries for functional screens using a diazotizing reagent
Meng, G., Guo, T., Ma, T., Zhang, J., Shen, Y., Sharpless, K. B., & Dong, J. (2019) · Nature · doi:10.1038/s41586-019-1589-1 · Cited by 357
Kuljanin, M., Mitchell, D. C., Schweppe, D. K., Gikandi, A. S., Nusinow, D. P., Bulloch, N. J., Vinogradova, E. V., Wilson, D. L., Kool, E. T., Mancias, J. D., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00778-3 · Cited by 305
Friberg, A., Vigil, D., Zhao, B., Daniels, R. N., Burke, J. P., Garcia-Barrantes, P. M., Camper, D., Chauder, B. A., Lee, T., Olejniczak, E. T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301448p · Cited by 300
Natural-product-derived fragments for fragment-based ligand discovery
Over, B., Wetzel, S., Grütter, C., Nakai, Y., Renner, S., Rauh, D., & Waldmann, H. (2013) · Nature Chemistry · doi:10.1038/nchem.1506 · Cited by 300
Modulating protein–protein interactions: the potential of peptides
Nevola, L., & Giralt, E. (2015) · Chemical Communications · doi:10.1039/c4cc08565e · Cited by 289
Smith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Next generation 3D pharmacophore modeling
Schaller, D., Šribar, D., Noonan, T., Deng, L., Nguyen, T. N., Pach, S., Machalz, D., Bermudez, M., & Wolber, G. (2020) · WIREs Computational Molecular Science · doi:10.1002/wcms.1468 · Cited by 269
Route to three-dimensional fragments using diversity-oriented synthesis
Hung, A. W., Ramek, A., Wang, Y., Kaya, T., Wilson, J. A., Clemons, P. A., & Young, D. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015271108 · Cited by 268
Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100060b · Cited by 264
Self-citationTheory and applications of differential scanning fluorimetry in early-stage drug discovery
Gao, K., Oerlemans, R., & Groves, M. R. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00619-2 · Cited by 263
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Link-INVENT: Generative Linker Design with Reinforcement Learning
Guo, J., Knuth, F., Margreitter, C., Janet, J. P., Papadopoulos, K., Engkvist, O., & Patronov, A. (2022) · doi:10.26434/chemrxiv-2022-qkx9f · Cited by 101
Chessari, G., Buck, I. M., Day, J. E. H., Day, P. J., Iqbal, A., Johnson, C. N., Lewis, E. J., Martins, V., Miller, D., Reader, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00706 · Cited by 90
Self-citationFragment Informatics and Computational Fragment‐Based Drug Design: An Overview and Update
Sheng, C., & Zhang, W. (2013) · Medicinal Research Reviews · doi:10.1002/med.21255 · Cited by 80
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Hahne, G., & Grossmann, T. N. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.050 · Cited by 46
Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2
Silva-Santisteban, M. C., Westwood, I. M., Boxall, K., Brown, N., Peacock, S., McAndrew, C., Barrie, E., Richards, M., Mirza, A., Oliver, A. W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065689 · Cited by 31
“Fragment-based drug discovery (FBDD), which in the last 10 years has become established as an attractive approach in drug discovery, involves the screening of a relatively small library, typically of 500 to 2000 compounds of low complexity and low molecular weight [41,42,43,44].”
BackgroundSIGLEC-4 (MAG) antagonists: From the natural carbohydrate epitope to glycomimetics
Schwardt, O., Kelm, S., & Ernst, B. (2013) · Topics in current chemistry · doi:10.1007/128_2013_498 · Cited by 14
Wranik, M., Kepa, M. W., Beale, E. V., James, D., Bertrand, Q., Weinert, T., Furrer, A., Glover, H., Gashi, D., Carrillo, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43523-5 · Cited by 14
eEF2K Inhibitor Design: The Progression of Exemplary Structure-Based Drug Design
Klupt, K. A., & Jia, Z. (2023) · Molecules · doi:10.3390/molecules28031095 · Cited by 11
McNerlin, C., Guan, F., Bronk, L., Lei, K., Grosshans, D., Young, D. W., Gaber, M. W., & Maletic-Savatic, M. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.07.007 · Cited by 11
Utgés, J. S., MacGowan, S. A., Ives, C. M., & Barton, G. J. (2024) · Communications Biology · doi:10.1038/s42003-024-05970-8 · Cited by 10
Accessing Active Fragments for Drug Discovery Utilising Nitroreductase Biocatalysis
Holder, L., Yuce, E., Oriomah, G., Jenkins, A., Reynisson, J., Winter, A., & Cosgrove, S. C. (2024) · ChemBioChem · doi:10.1002/cbic.202400428 · Cited by 2
Metadata
- Authors
- Murray, C. W., & Rees, D. C.
- Venue
- Nature Chemistry
- Published
- 2009-06
- Volume
- 1
- Issue
- 3
- Pages
- 187-192
- ISSN
- 1755-4330 (ISSN-L)
- 1755-4349
- OpenAlex
- W2046813714
- Cited by
- 791
- References
- 48
- FWCI
- 32.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.